Brand Drugs Have Disadvantage In HHS’ Proposed Actuarial Value Calculator For Plans, PhRMA Says
Executive Summary
In comments addressing the HHS proposed rule on essential health benefits required for private individual and small group plans, PhRMA argues there are “several” aspects of the mechanism to calculate plan actuarial value that may lead to member confusion regarding brand coverage.